Article Details
Retrieved on: 2024-07-25 20:41:44
Tags for this article:
Click the tags to see associated articles and topics
Summary
Cue Biopharma restructures to focus on autoimmune programs while continuing oncology trials. This strategic shift leverages biotechnology to modulate T cells, enhance operational efficiency, and reduce costs, targeting transformative immunotherapies.
Article found on: portal.sina.com.hk
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here